No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
12 Health Care Stocks Moving In Monday's Pre-Market Session
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Cuts Target Price to $48
Wedbush Adjusts Price Target on Edgewise Therapeutics to $40 From $43, Maintains Outperform Rating
Edgewise Therapeutics' Q1 Net Loss Widens; Shares Down Over 3%
Edgewise Therapeutics | 10-Q: Q1 2025 Earnings Report
Edgewise Therapeutics | 8-K: Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights